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A B S T R A C T
Objective: Data about the impact of growth hormone treatment (GHT) on insulin sensitivity in children are quite
controversial, due to the diﬀerent surrogate indices that have been used.
Design: We evaluated insulin sensitivity through the euglycemic hyperinsulinemic clamp, considered the gold
standard technique, in 23 children aﬀected by growth hormone deﬁciency (GHD) at baseline and after
12 months of GHT and in 12 controls with short stature at baseline, and we compared the clamp-derived index
(M-value) with the most commonly used surrogate index of insulin sensitivity, as ISI Matsuda, and with circu-
lating plasma markers of insulin sensitivity, as adiponectin and resistin levels.
Results: At baseline, no signiﬁcant diﬀerence in all metabolic parameters between GHD children and control
subjects was found. After 12 months of GHT, GHD children showed a signiﬁcant increase in fasting insulin
(p < 0.001) and resistin (p= 0.028) and a decrease in ISI Matsuda (p < 0.001) and M-value (p < 0.001),
without signiﬁcant change in fasting glucose, HbA1c and adiponectin. In GHD children, M-value showed a
signiﬁcant but weak correlation with ISI Matsuda (rho 0.418, p= 0.047) at baseline, while no correlation with
other parameters was found. After 12 months of GHT, M-value did not show any signiﬁcant correlation with any
other metabolic parameter analyzed.
Conclusions: This study highlights the limit of the evaluation of insulin sensitivity performed through surrogate
indices or circulating markers, which may lead to controversial data and do not correlate with the gold standard
technique to evaluate insulin sensitivity.
1. Introduction
It is widely known that growth hormone (GH), in addition to its
auxological eﬀects, exerts an anti-insulin eﬀect which can potentially
induce changes in carbohydrate metabolism [1]. GH treatment (GHT) is
associated with a tendency toward insulin resistance and a number of
clinical indices have been used in children aﬀected by GHD to assess the
impact of GHT on insulin sensitivity, with various and conﬂicting re-
sults. For these reasons, a reliable assessment of insulin sensitivity in a
population potentially at risk of impaired insulin sensitivity, like GHD
patients during GHT, is mandatory. Unfortunately, most of the indices
routinely used in clinical practice are derived from fasting glucose and
insulin levels and have not always proved to be to be reliable measures
of insulin sensitivity in healthy children [2]. Indeed, the gold standard
for assessing insulin sensitivity is euglycemic hyperinsulinemic clamp
[3] and Schwarts et al. demonstrated that most commonly used indices
of insulin sensitivity are not widely correlated with the clamp [2]. Si-
milarly, in a previous study including a small cohort of GHD children
we demonstrated a lack of correlation between the clamp-derived M-
value and other surrogate indices of insulin sensitivity, like Homa-IR or
QUICKI, which did not represent reliable indices of the insulin sensi-
tivity degree [4].
However, clamp is an invasive and expensive procedure and it is
diﬃcult to apply it routinely in clinical practice, especially in a large
number of children. Consequently, reliable data on insulin sensitivity
derived by clamp in GHD children are very scarce.
As plasma markers of insulin sensitivity, the circulating levels of
some adipokines, such as adiponectin and resistin, have been evaluated
in GHD but with very discordant data across the studies. In addition, no
data about the relationship among adipokines and clamp are available
in GHD children. Therefore, the reliability of adipokine levels is not
entirely known.
The aim of this study was to use the hyperinsulinemic clamp to
evaluate the impact of GHT on insulin-stimulated glucose utilization in
a group of children aﬀected by GHD and to compare the clamp-derived
index with the most commonly used surrogate indices and plasma
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markers of insulin sensitivity.
2. Materials and methods
We prospectively studied 23 prepubertal children (15 M, 8 F, mean
age 8.4 ± 1.0 years; range 6.1–9.9) with isolated idiopathic GHD
consecutively admitted to the Section of Endocrinology of the
University of Palermo during the years 2014–2015 and treated with GH
for at least 12 months and never investigated before in other clinical
studies. Twelve prepubertal healthy subjects with short stature (7 M,
5 F) matched for age (mean age 7.8 ± 0.9 years; range 5.6–9.4) were
recruited among children referred for assessment of short stature as a
control group at baseline. All children were in the ﬁrst stage of sexual
development during the full observation period to avoid any inter-
ference of the onset of puberty with metabolic parameters. Similarly,
children with multiple pituitary hormone deﬁciencies were excluded
from the study to avoid any potential interference of untreated hor-
monal deﬁciency or of other hormonal replacement therapy on meta-
bolic data.
GHD was diagnosed by the auxological and biochemical criteria of
the GH Research Society [5]. As auxological data we considered height
and growth velocity 1 year before diagnosis, while we considered a
bone age delay, estimated from an X-ray of the left wrist and hand and
evaluated according to the methods of Greulich and Pyle, of at least
1 year with respect to the chronological age [6]. Biochemically, GHD
was demonstrated by failure of GH to respond to an arginine and glu-
cagon stimulation test, performed on two diﬀerent days. Speciﬁcally,
GH peak was below 7 μg/l in 3 children, below 6 μg/l in 6 children,
below 5 μg/l in 9 children and below 3 μg/l in 5 children. Since the
classiﬁcation of GHD in moderate or severe is quite arbitrary, we con-
sidered a GH peak below 8 μg/l as diagnostic for overt GHD, in line
with the criteria of appropriateness of use and reimbursement of GHT in
children according to the Italian Medicines Agency (AIFA). Neuroima-
ging of the hypothalamic-pituitary region, in line with our protocol,
was performed in children with more severe GHD, like those with GH
peak ≤3 μg/l during both tests (5 children) and showed no pituitary
alterations.
The patients received GH once daily at bedtime. During the entire
follow-up, insulin-like growth factor (IGF)-I levels allowed us to de-
termine the GH dose. Speciﬁcally, the initial daily dose of GH was
0.025 mg/kg, increased to 0.027 mg/kg from monthS 6 to 12.
2.1. Study protocol
In all GHD patients the auxological and metabolic evaluation was
performed at baseline and after 12 months of GH treatment, while in
controls these evaluations were only performed at baseline. In all
children we measured body height, body mass index (BMI) and waist
circumference (WC). A blood sample was drawn after an overnight fast
for the measurement of glucose, insulin, Hemoglobin A1c (HbA1c) and
IGF-I. This sample served as the baseline for the oral glucose tolerance
test (OGTT). Blood samples were collected every 30 min for 120 min for
glucose and insulin measurements.
As surrogate estimates of insulin sensitivity we used the insulin
sensitivity index, a composite index derived from the OGTT and vali-
dated by Matsuda and DeFronzo (ISI-Matsuda) [7].
On a diﬀerent day, as a gold standard measurement of insulin sen-
sitivity we performed the euglycemic hyperinsulinemic clamp. As per
our protocol, one catheter was placed in a vein on the forearm for
administration of insulin and glucose and the second catheter was
placed in retrograde direction in an antecubital vein of the contralateral
heated forearm for obtaining arterialized venous blood, using an air-
heated box at approximately 55 °C. The clamp was performed under
standard conditions, i.e. the plasma insulin concentration was acutely
raised with insulin priming (0–3 min: 113.6 mU/m2, 3–6 min:
80.2 mU/m2, 7–10 min: 50.4 mU/m2 of body surface area) for the ﬁrst
10 min of the test and maintained by continuous infusion of insulin
infusion (40 mU/m2 for the remaining 110 min). The rate of peripheral
glucose utilization (M value) was calculated by dividing the glucose
amount infused during the last 40 min by body weight measured in
kilograms (mg/kg/min). The plasma glucose concentration was held
constant at basal levels by variable glucose infusion and under the
steady-state conditions of euglycemia the glucose infusion rate equaled
glucose uptake by all the tissues in the body and it was therefore con-
sidered a measure of tissue sensitivity to exogenous insulin [3].
Multiple pituitary hormone deﬁciency at baseline was excluded by
the evaluation of normal basal cortisol levels (which were≥18 μg/l in
all children) and free thyroxine (FT4). After 12 months of GHT, in 7
children who showed basal cortisol levels< 18 μg/l we performed a
low-dose short adrenocorticotropin test, which showed a normal cor-
tisol response.
As circulating insulin sensitivity markers, the serum levels of adi-
ponectin and resistin after an overnight fast were also measured. The
institutional Ethics Committee of the University of Palermo approved
this study. At the time of hospitalization, an informed consent for the
scientiﬁc use of the data was obtained from both the participants and
their parents.
2.2. Hormone and biochemical assays
Glucose was measured in the centralized accredited laboratories of
the University of Palermo with the standard methods. HbA1c levels
were determined by HPLC with an ion-exchange resin (BioRad D10,
BioRad, Milan, Italy). Serum insulin was measured by electro-
chemiluminescence (ECLIA, Elecsys Insulin, Roche, Milan, Italy). The
sensitivity of the method was 0.4 μU/ml. The normal range (μU/ml)
was 2.6–24.9. Serum GH levels were measured by Immunoassay in
electrochemiluminescence (ECLIA, Elecsys hGH, Roche, Milan, Italy).
The lower limit of detection of the assay was 0.030 μg/l. The intra- and
inter-assay coeﬃcients of variation (CV) were 0.6–5.0 and 3.8–5.0%,
respectively. We reported GH concentrations in μg/l of IS 98/574.
Serum IGF-I levels were measured by means of a chemiluminescent
immunometric assay (Immulite 2000; Diagnostic Products Corp., Los
Angeles, CA) using murine monoclonal anti-IGF-I antibodies. The
standards were calibrated against the World Health Organization
second IS 87/518. The sensitivity was 1.9 μg/l. The intra- and inter-
assay CVs were 2.3–3.9% and 3.7–8.1%, respectively. Adiponectin (μg/
ml) and resistin (ng/ml) were assayed using an ELISA sandwich enzyme
immuno-assay (BioVendor, Heidelberg, Germany).
2.3. Statistical analysis
The Statistical Packages for Social Sciences SPSS version 19 was
used for data analysis. Baseline characteristics were presented as
mean ± SD for continuous variables. Normality of distribution for
quantitative variables was assessed with the Kolmogorov-Smirnov test.
The diﬀerences between GHD and controls were analyzed by Student's
t-test, except for GH peak after glucagon and arginine test and fasting
insulin levels, which were analyzed by Mann–Whitney U test (non-
parametric test), as they were continuous variables without normal
distribution. The diﬀerences between paired continuous variables in the
GHD group (before and 12 months after GHT) were analyzed using the
paired Student's t-test for continuous variables, except for fasting in-
sulin levels, which were analyzed by the Wilcoxon test. Pearson's cor-
relation was performed among continuous variables. A p value< 0.05
was considered statistically signiﬁcant.
3. Results
3.1. Clinical and hormonal parameters
The clinical and hormonal features of control subjects and GHD
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children at diagnosis and after 12 months of GHT are shown in Table 1.
At baseline, no signiﬁcant diﬀerence in height, BMI and WC be-
tween GHD children and controls was found. As expected, GHD chil-
dren showed signiﬁcantly lower growth velocity (3.5 ± 0.8 vs.4.7 ±
0.9 cm; p < 0.001), IGF-I (−0.7 ± 0.2 vs. 1.1 ± 0.4 SDl;
p < 0.001) and GH peak after both glucagon (4.4 ± 1.7 vs.
11.1 ± 1.7 μg/l; p < 0.004) and arginine test (4.1 ± 2.0 vs.
16.6 ± 6.0 μg/l; p < 0.001) than control subjects.
In GHD children after 12 months we observed a signiﬁcant increase
in growth (height: −1.8 ± 0.1 vs. −2.2 ± 0.2 SDS; p < 0.001;
growth velocity: 7.7 ± 1.8 vs. 3.5 ± 0.8 cm; p < 0.001), with a
concomitant increase in IGF-I (1.0 ± 0.3 vs. -0.7 ± 0.2 SD;
p < 0.001), while no signiﬁcant change in BMI and WC was found
(Table 1).
3.2. Metabolic parameters
The metabolic parameters of control subjects and GHD children at
diagnosis and after 12 months of GHT are shown in Table 1.
At baseline, no signiﬁcant diﬀerence was found in fasting glucose,
insulin and HbA1c between GHD children and controls. Similarly, no
signiﬁcant diﬀerence was found in ISI Matsuda, M-value (Fig. 1) adi-
ponectin and resistin levels between the 2 groups (Table 1).
After 12 months of GHT, GHD children showed a signiﬁcant in-
crease in fasting insulin (9.5 ± 5.0 vs. 4.2 ± 2.0I/ml; p < 0.001),
with a concomitant signiﬁcant decrease in ISI Matsuda (5.0 ± 1.8 vs.
11 ± 3.6; p < 0.001) and M-value (3.7 ± 0.7 vs. 4.8 ± 0.5 mg/kg/
min; p < 0.001) (Fig. 1), without signiﬁcant change in fasting glucose,
and HbA1c (Table 1). Adiponectin levels did not show any signiﬁcant
change after GHT (11.8 ± 2.6 vs. 11.6 ± 2.3 μg/ml; p= 0.649),
while a signiﬁcant increase in resistin levels (4.6 ± 2.1 vs.
3.9 ± 1.1 ng/ml; p= 0.028) was found.
At baseline, GHD children showed a signiﬁcant and weak correla-
tion between M-value and ISI Matsuda (rho 0.418, p= 0.047), while no
correlation was found between M-value and BMI, WC, adiponectin,
resistin and IGF-I. After 12 months of GHT, the M-value did not show
any signiﬁcant correlation with any other metabolic parameter ana-
lyzed (Table 2). The additional analysis evaluating the correlation be-
tween the delta (change from baseline to 12 months) of the parameters
evaluated in the model did not show any signiﬁcant correlation be-
tween the delta of M-value and that of the dependent variables (data
not shown). No correlation was found among ISI Matsuda, adiponectin
and resistin levels (data not shown).
4. Discussion
In this study we found that 12 months of GHT lead to a deterioration
in insulin sensitivity, although the glucose tolerance seems to be un-
aﬀected, and that the euglycemic hyperinsulinemic clamp, considered
as the gold standard technique to assess insulin sensitivity, does not
correlate with the other surrogate indices routinely used in clinical
Table 1
Clinical and biochemical features of control subjects and GHD children at diagnosis (baseline) and after 12 months of GH treatment. Data are presented as rates and proportions for the
categorical data and as mean ± standard deviation (SD) for the continuous variables.
Control group (N. 12) GHD at baseline (N. 23) GHD at 12 months (N. 23) p p⁎
Gender 0.483 –
Males 7 (58) 15 (65) 15 (65)
Females 5 (42) 8 (35) 8 (35)
Mean ± SD Mean ± SD Mean ± SD
Age (years) 7.8 ± 0.9 8.4 ± 1.0 – 0.086 –
Height (SD) −2.1 ± 0.1 −2.2 ± 0.2 −1.8 ± 0.1 0.072 < 0.001
Growth velocity (cm/year) 4.7 ± 0.9 3.5 ± 0.8 7.7 ± 1.8 < 0.001 < 0.001
BMI (kg/m2) 17.1 ± 2.8 17.2 ± 2.3 17.6 ± 2.5 0.939 0.306
WC (cm) 64.2 ± 10.7 62.5 ± 10.2 63.7 ± 9.3 0.640 0.086
IGF-I (SD) 1.1 ± 0.4 −0.7 ± 0.2 1.0 ± 0.3 < 0.001 < 0.001
GH peak after glucagon test (μg/l) 11.1 ± 1.7 4.4 ± 1.7 – < 0.001 –
GH peak after arginine test (μg/l) 16.6 ± 6.0 4.1 ± 2.0 – < 0.001 –
Fasting glucose (mmol/L) 78.9 ± 3.3 82.9 ± 9.0 87.1 ± 11.9 0.067 0.101
HbA1c (%) 5.1 ± 0.3 5.2 ± 0.2 5.3 ± 0.3 0.713 0.053
Fasting insulin (IU/ml) 3.3 ± 2.0 4.2 ± 2.0 9.5 ± 5.0 0.220 < 0.001
ISI-Matsuda 12.3 ± 3.7 11 ± 3.6 5 ± 1.8 0.343 < 0.001
M-value (mg/kg/min) 4.5 ± 0.5 4.8 ± 0.5 3.4 ± 0.7 0.064 < 0.001
Adiponectin (μg/ml) 12.8 ± 3.5 11.6 ± 2.3 11.8 ± 2.6 0.219 0.649
Resistin (ng/ml) 3.2 ± 0.8 3.9 ± 1.1 4.6 ± 2.1 0.274 0.028
p = diﬀerence between control group and GHD subjects at baseline.
p*= diﬀerence between GHD subjects at baseline and GHD subjects at 12 months of GH treatment.
Fig. 1. M-value (clamp-derived) and ISI-Matsuda of control subjects and GHD children at
diagnosis and after 12 months of GH treatment.
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practice.
It is known that GH, in addition to its auxological eﬀects, plays a key
metabolic role [1]. If these metabolic eﬀects are frequently unnoticed in
the pediatric age, probably due to the short duration of GHD compared
with adult patients, they occur more often during GHT. Indeed, in our
cohort of patients at baseline no signiﬁcant diﬀerence was found in all
metabolic parameters analyzed.
Increased insulin resistance, through impaired suppression of glu-
cose production and impaired stimulation of glucose utilization, has
been demonstrated after continuous GH infusion [8]. GHT is associated
with an increase in insulin levels, although whether GH-induced hy-
perinsulinemia should be considered an index of relative insulin re-
sistance is not clear. Indeed, a deterioration of the basal indices of in-
sulin resistance, like Homa-IR, is widely demonstrated by many studies
performed in GHD children [9–11].
Conversely, based on Homa-IR values, Capalbo et al. recently re-
ported that GHT is not associated with signiﬁcant impairment of insulin
sensitivity in GHD children [12]. These discordant data are probably
due to the inability of Homa-IR to reliably assess insulin sensitivity.
Indeed, the increase in Homa-IR may just represent an expected con-
sequence of GH-induced basal hyperinsulinemia and may lead to dis-
cordant results. These data are conﬁrmed by the current study. Indeed,
we found a signiﬁcant increase in fasting insulin after 12 months of
GHT, even without evident changes in glucose tolerance, as demon-
strated by the unchanged glucose and HbA1c levels.
Certainly ISI Matsuda, which derives from glucose and insulin levels
during OGTT, shows a diﬀerent behavior and represents a more reliable
index of insulin sensitivity than the basal Homa-IR [13]. In this study,
as expected, we found a signiﬁcant decrease in ISI Matsuda after GHT.
However, available data about a relationship between ISI Matsuda and
other indices of insulin sensitivity, such as the gold standard clamp [4]
or with adipokine levels [14], are scarce and do not seem to conﬁrm the
full reliability of this index.
In this study we aimed to assess the performance of both ISI
Matsuda and the gold standard clamp. These data suggest that ISI
Matsuda may be useful to detect changes in insulin sensitivity, although
a weak correlation to M-value (at baseline) and no correlation (after
12 months of GHT) were reported. In our opinion, probably the small
number of sample may be the cause of the lack of correlation between
the 2 indices although, in this connection, comparative data about the
insulin sensitivity degree in GHD children assessed by these 2 indices
are unavailable from literature.
In a large group of childhood cancer survivors with GHD in whom
insulin sensitivity was measured by euglycemic hyperinsulinemic
clamp, Petryk et al. showed lower M value than controls [15], while in
the current study we did not ﬁnd any signiﬁcant diﬀerence in M-value
between GHD and controls, probably due to the major diﬀerence in
patients evaluated. A signiﬁcant impact of GHT on M-value has been
reported by Norrelund et al., who showed an increase in insulin sen-
sitivity after 12 months of discontinuation of GHT in 18 GHD patients
during transition from childhood to adulthood, with a subsequent de-
terioration when GHT was restarted [16].
We have previously reported similar results in a small group of
prepubertal GHD children, in whom we showed a signiﬁcant dete-
rioration in M-value after 12 months of GHT [4]. The current study,
performed in a larger cohort of patients, conﬁrms these data. Indeed, a
signiﬁcant decrease in insulin sensitivity assessed by clamp was docu-
mented after GHT. The mechanisms of the deterioration of insulin
sensitivity during GHT are probably multiple and related to the
counter-regulatory action of the GH, since neither IGF-I nor BMI or WC
individually showed a signiﬁcant correlation with M-value.
Circulating plasma markers of insulin sensitivity, such as some
adipokines, have been tested in GHD children. Adiponectin levels are
recognized to be inversely related to insulin resistance [17]. GH has
been shown to decrease the expression of adiponectin in cultured
human adipose tissue [18]. However, data about the impact of GHT on
adiponectin are quite controversial. Adiponectin seems to be unaﬀected
in untreated GHD [19] and GHT seems to have discordant eﬀects on
adiponectin, leaving it unchanged or only slightly modifying it
[11,19–22]. Conversely, an increase in adiponectin has been docu-
mented in GHD children by other studies [23,24]. The available data
about the relationship between adiponectin levels and insulin sensi-
tivity indices are very scarce. We found a lack of correlation between
insulin sensitivity and change in adiponectin levels, in agreement with
previous studies. Indeed, Hana et al. showed that GHT in adult GHD is
eﬀective in changing body composition but without concomitant
changes in adiponectin levels [20]. Similarly, we already demonstrated
that the change in insulin sensitivity during GHT in children, assessed
with both Homa-IR and ISI Matsuda, is not concomitant with change in
adiponectin levels [11,14] and similar results have been obtained by
other studies [24].
Resistin has been shown to be linked to insulin resistance [25], but
the few available data about the impact of GHD or GHT on its circu-
lating levels are quite controversial. No diﬀerence in resistin levels
between adult GHD patients and controls was reported by Salman et al.
[26] and our current data are in agreement with that study. Indeed,
resistin levels showed no signiﬁcant diﬀerence between GHD children
at baseline and controls. Although marked and sustained up-regulation
of resistin by GH has been demonstrated [27]. Meazza et al. showed
higher resistin levels in 17 GHD children and a subsequent decrease in
these levels after 12 months of GHT [28], while other studies showed
that GHT does not seem able to signiﬁcantly modify resistin levels in
adult GHD patients [26].
In a previous report we showed a trend to an increase in resistin,
though not statistically signiﬁcant, in children during GHT [14]. Si-
milarly, Nozue et al. reported a rise in resistin after 1 months of GHT in
20 children, regardless of change in other metabolic parameters [29]
and our study conﬁrms this ﬁnding, showing a rise in resistin after GHT.
These controversial data about adipokine levels indicate that the
change in them are probably not really correlated with the change in
insulin sensitivity degree, as demonstrated by the lack of correlation
among adipokine levels and M-value shown in the current study.
Indeed, if at baseline we found that clamp showed a correlation, even
fairly weak, only with ISI Matsuda and not with adipokine levels, after
12 months of GHT the adipokine levels did not show a correlation with
clamp. In our opinion a number of factors, ﬁrst of all the fat mass, may
inﬂuence adipokine levels and make them unreliable markers, since the
amount of fat mass is not necessarily correlated with the quality of fat.
A limitation of this study may certainly be related to the small size
of the population. Indeed, we believe that these data must be validated
in additional larger prospective studies. However, clamp represents an
invasive and expensive procedure and therefore it is diﬃcult to apply
routinely in clinical practice, especially in children. Other limitations
may be represented by the short-term follow-up and the lack of data of
the control group after 12 months of follow-up. Although the main
metabolic eﬀects of GHT generally occur during the ﬁrst months of
Table 2
Correlation (univariate analysis) between M-value derived by euglycemic hyper-
insulinemic clamp and hormonal and metabolic parameters at baseline and after
12 months of GH treatment in GHD children.
Independent variables Dependent variable: M-value (clamp-derived)
Baseline 12 months
r p r p
IGF-I (SD) −0.138 0.529 −0.112 0.611
BMI (kg/m2) −0.137 0.534 −0.005 0.983
WC (cm) −0.026 0.906 −0.093 0.673
ISI Matsuda 0.418 0.047 0.052 0.813
Adiponectin (μg/ml) 0.032 0.884 0.264 0.223
Resistin (ng/ml) −0.274 0.205 0.073 0.740
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treatment, a longer follow-up may be useful to have more reliable data,
both in GHD children and control subjects. In addition, adding data on
body composition evaluated by dual energy X-ray absorptiometry
(DEXA) will certainly conﬁrm these important data in future studies.
Conversely, the strength of this study lies in the fact that for the ﬁrst
time it simultaneously evaluated the clamp with other indices and
plasma markers of insulin sensitivity in GHD children.
In conclusion, this study highlights the limit of the evaluation of
insulin sensitivity performed through surrogate indices or circulating
markers, such as adipokines, which may lead to controversial data and
do not correlate with the gold standard technique to assess insulin
sensitivity.
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